Nontuberculosis Mycobacterium Contamination of a Mammalian Cell Bioreactor Process - The authors present a case study identifying a contaminant. - BioPharm International

ADVERTISEMENT

Nontuberculosis Mycobacterium Contamination of a Mammalian Cell Bioreactor Process
The authors present a case study identifying a contaminant.


BioPharm International
Volume 24, Issue 6, pp. 30-34

IMPLICATIONS FOR THE INDUSTRY

The nontuberculosis mycobacteria appear to represent a potential risk to the biopharmaceutical industry, due to their propensity for forming biofilms, their ability to proliferate in water under relatively low nutrient conditions, their resistance to typical water disinfection methods, and their relatively slow growth in nutrient media (2–5). The former properties render these organisms capable of existing in water piping and other surfaces in contact with water or aqueous media. Their growth characteristics make these agents easy to overlook, especially when surveillance methods, such as short-term bioburden assays, are employed. In this case study, the bioreactor run was terminated early because of an overly high value for an in-process monitoring parameter. However, routine bioburden testing performed on bulk harvest samples taken from the terminated bioreactor failed to detect the presence of the mycobacterial contaminant. Eventual detection of the contaminant in the course of adventitious virus testing of this bioreactor harvest sample was possible because that assay was relatively long in duration (28 days) and the antibiotics used in the assay (gentamicin, amphotericin B) were apparently ineffective against the species of mycobacterium involved. The route of entry of the mycobacterium into the bioreactor process was not determined.

The mycobacteria involved in this case are pathogenic in humans, especially those who are immunocompromised (6, 7). It is difficult to estimate the frequency of occurrence of mycobacterial contamination in the biologics manufacturing industry, because some episodes may lead to premature bioreactor termination, such as that occurring in this case, with little evidence to implicate a mycobacterium. A few cases of contaminated vaccines and tissue extracts have been reported in the literature (8, 9). One can only speculate about the actual risk to the biopharmaceutical industry of this type of contamination.

At the time the work was performed1, Raymond Nims, PhD*, was a scientific director, Alfred Chun, was a laboratory director, Angela Marino, was a laboratory supervisor, and Suzanne Dieringer-Boyer, was a scientist, all at Biologics Testing at BioReliance, Rockville, MD,
.

REFERENCES

1. R. Nims et. al., "Adventitious Agents: Concerns and Testing for Biopharmaceuticals," in: Process Validation in Manufacturing of Biopharmaceuticals: Guidelines, Current Practices, and Industrial Case Studies, A.S. Rathore and G. Sofer, Eds., (CRC Press, Boca Raton, FL, 2005), pp. 143–167.

2. C. Le Dantec et al., Appl. Environ. Microbiol. 68 (11), 5318–5325 (2002).

3. L. Hall-Stoodley, C.W. Keevil, and H.M. Lappin-Scott, J. Appl. Microbiol. 85, 60S–69S (1999).

4. L. A. Carson et. al., Appl. Environ. Microbiol. 36 (6), 839–846 (1978).

5. C. Le Dantec et. al., Appl. Environ. Microbiol. 68 (3), 1025–1032 (2002).

6. B.G. Metchock et. al., "Mycobacterium," in: Manual of Clinical Microbiology, Murray, et al., Eds., (ASM Press, 7th ed., 1999) pp. 399–437.

7. W.J. Koh, O.J. Kwon, and K.S. Lee, Korean J. Radiol. 3 (3), 145–157 (2002).

8. J.G.A. Borghans and J.L. Stanford, Am. Rev. Respir. Dis. 107 (1), 1–8 (1973).

9. K. Galil et al., Emerg. Inf. Dis. 5 (5), 681–687 (1999).

1 Current Author Affiliations:
Raymond Nims is currently at RMC Pharmaceutical Solutions, Inc., Longmont, CO, Alfred Chun is currently at Cangene bioPharma, Baltimore, MD, and Suzanne Dieringer-Boyer is currently at the National Biodefense Analysis and Countermeasures Center (NBACC), Frederick, MD.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Novartis Sells Influenza Vaccine Business to CSL for $275 Million
October 27, 2014
Author Guidelines
Source: BioPharm International,
Click here